Sofosbuvir and ledipasvir improve patient-reported outcomes in patients co-infected with hepatitis C and human immunodeficiency virus

Journal of Viral Hepatitis

Volumn 23, Issue 11, 2016, Pages 857-865

  Younossi, Z M ^a,b   Stepanova, M ^c   Sulkowski, M ^d   Naggie, S ^e   Henry, L ^c   Hunt, S ^c  

^a INOVA FAIRFAX HOSPITAL   (United States)

^b BETTY AND GUY BEATTY CENTER FOR INTEGRATED RESEARCH   (United States)

^c Center for Outcomes Research in Liver Diseases   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

HCV; HIV; HRQL; LDV SOF; patient reported outcomes; work productivity

Indexed keywords

ANTIVIRUS AGENT; LEDIPASVIR PLUS SOFOSBUVIR; RIBAVIRIN PLUS SOFOSBUVIR; UNCLASSIFIED DRUG; BENZIMIDAZOLE DERIVATIVE; FLUORENE DERIVATIVE; LEDIPASVIR; SOFOSBUVIR;

ABDOMINAL PAIN; ADULT; ARTICLE; ASTHENIA; BLOATING; CAUCASIAN; CHRONIC LIVER DISEASE QUESTIONNAIRE HEPATITIS C VIRUS SCORE; COHORT ANALYSIS; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FUNCTIONAL ASSESSMENT OF CHRONIC ILLNESS THERAPY FATIGUE SCORE; GASTROINTESTINAL DISEASE; GENOTYPE; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MIXED INFECTION; NAUSEA; NEUROLOGIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATIENT-REPORTED OUTCOME; PREDICTION; PRIORITY JOURNAL; QUALITY OF LIFE; SCORING SYSTEM; SHORT FORM 36; TREATMENT DURATION; VOMITING; WORK PRODUCTIVITY AND ACTIVITY SPECIFIC HEALTH PROBLEM SCORE; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; HEPATITIS C, CHRONIC; MIDDLE AGED; PATIENT SATISFACTION; PRODUCTIVITY; TREATMENT OUTCOME;

ADULT; ANTIVIRAL AGENTS; BENZIMIDAZOLES; EFFICIENCY; FATIGUE; FEMALE; FLUORENES; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PATIENT SATISFACTION; SOFOSBUVIR; TREATMENT OUTCOME;

EID: 84977488523     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12554     Document Type: Article

References (29)

1. Lawitz E, Mangia A, Wyles D et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368(20): 1878–1887.
2. Poordad F, Lawitz E, Kowdley KV et al. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med 2013; 368(1): 45–53.
3. Jacobson IM, Gordon SC, Kowdley KV et al. N Engl J Med 2013; 368(20): 1867–1877.
4. Afdhal N, Zeuzem S, Kwo P et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370(20): 1889–1898.
5. Afdhal N, Reddy KR, Nelson DR et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370(16): 1483–1493.
6. Zeuzem S, Dusheiko GM, Salupere R et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014; 370(21): 1993–2001.
7. Kowdley KV, Gordon SC, Reddy KR et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014; 370(20): 1879–1888.
8. Ferenci P, Bernstein D, Lalezari J et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014; 370(21): 1983–1992.
9. Lawitz E, Sulkowski MS, Ghalib R et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014; 384(9956): 1756–1765.
10. Nelson DR, Cooper JN, Lalezari JP et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 2015; 61(4): 1127–1135.
11. Sulkowski MS, Naggie S, Lalezari J et al. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA 2014; 312(4): 353–361.
12. Naggie S, Cooper C, Saag M et al. Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med 2015; 373(8): 705–713.
13. Baran RW, Xie W, Liu Y, Cohen DE, Gooch K. Health related quality of Life (HRQoL), health state, function and wellbeing of chronic HCV patients treated with interferon-free, oral DAA regimens: patient reported outcome (PRO) results from the Aviator study. Poster presented at: 64th Annual Meeting of the American Association for the Study of Liver Disease: Nov 1–5 2013; Washington, DC. p. 1113.
14. Younossi ZM, Stepanova M, Henry L et al. Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2014; 12(8): 1349–1359.
15. Lo Re V, Tate J, Kallan M et al. Increased risk of hepatic decompensation and hepatocellular carcinoma in HIV/HCV-co-infected patients compared to HCV-mono-infected patients despite combination antiretroviral therapy. Proceedings of the 19th International AIDS Conference (IAC'12, Washington DC, USA), abstract WEAB0102. Available at: http://pag.aids2012.org/Abstracts.aspx?SID=213*AID=17867 (accessed 25 September 2014).
16. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006; 44(Suppl. 1): S6–S9.
17. Thein HH, Yi Q, Dore GJ, Krahn MD. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS 2008; 22(15): 1979–1991.
18. Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008; 372(9635): 293–299.
19. Smith CJ, Ryom L, Weber R et al. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet 2014; 384(9939): 241–248.
20. Younossi ZM, Stepanova M, Henry L et al. Minimal impact of sofosbuvir and ribavirin on health related quality of life in Chronic Hepatitis C (CH-C). J Hepatol 2014; 60(4): 741–747.
21. Younossi ZM, Stepanova M, Sulkowski M et al. Sofosbuvir and ribavirin for treatment of chronic hepatitis C in patients co-infected with HIV: the impact on patient-reported outcomes. J Infect Dis 2015; 212(3): 367–377.
22. Younossi ZM, Stepanova M, Marcellin P et al. Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: results from the ION-1, -2, and -3 clinical trials. Hepatology 2015; 61(6): 1798–1808.
23. Kallman J, O'Neil MM, Larive B, Boparai N, Calabrese L, Younossi ZM. Fatigue and health-related quality of life (HRQL) in chronic hepatitis C virus infection. Dig Dis Sci 2007; 52(10): 2531–2539.
24. Hays RD, Morales LS. The RAND-36 measure of health-related quality of life. Ann Med 2001; 33(5): 350–357.
25. Webster K, Odom L, Peterman A, Lent L, Cella D. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: validation of version 4 of the core questionnaire. Qual Life Res 1999; 8(7): 604.
26. Younossi ZM, Guyatt G, Kiwi M, Boparai N, King D. Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. Gut 1999; 45: 295–300.
27. Younossi Z, Henry L. Systematic review: patient-reported outcomes in chronic hepatitis C--the impact of liver disease and new treatment regimens. Aliment Pharmacol Ther. 2015 Mar; 41(6): 497–520. doi: 10.1111/apt.13090. Epub 2015 Jan 23. Review
28. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993; 4(5): 353–365.
29. Brazier JE, Rowen D, Hanmer J. Revised SF-6D Scoring Programmes: a Summary of Improvements. PRO Newsletter 2008. 40(Fall issue): 14–15. Last accessed on June 6, 2016 at:http://www.pro-newsletter.com/images/PDF/pron40-final.pdf